Is SINTX Technologies, Inc. overvalued or undervalued?

As of 29 March 2023, the valuation grade for SINTX Technologies, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 1.17, an EV to Sales ratio of 0.43, and a staggering ROCE of -822.40%.
In comparison to its peers, SINTX Technologies has a P/E ratio of -1.6293, while Vivos Therapeutics, Inc. and NeuroMetrix, Inc. have P/E ratios of -2.0072 and -1.2085, respectively, suggesting that SINTX is relatively better positioned among its risky peers but still reflects significant financial challenges. Recent stock performance shows that while SINTX had a strong 1-month return of 32.70%, it lagged behind the S&P 500's 2.33% return over the same period, reinforcing the notion of its overvaluation amidst a broader market recovery.